Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1 2

Status

Active not recruiting 126Recruiting 110Completed 68Terminated 27Not yet recruiting 11Withdrawn 7Suspended 1

Sponsor Class

OTHER 4NIH 2INDUSTRY 1

Study Type

Interventional 7

Sponsor

Cancer Type

Tumor-Agnostic 2Thoracic 2Other solid neoplasm 1Genitourinary 1Gastrointestinal 1

Conditions

Lung Neoplasms 2Urinary Bladder Neoplasms 1Neoplasm Metastasis 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Squamous Cell 1Advanced Solid Tumors 1

Interventions

pembrolizumab 19Magnetic Resonance Spectroscopy 13Specimen Handling 12Cyclophosphamide 10fludarabine 9Radiotherapy 9Biopsy 8atezolizumab 7Nivolumab 7Radiation 6Prednisone 4Gemcitabine 4Etoposide 4Cytarabine 4Cisplatin 4Carboplatin 4Blood Specimen Collection 4ALT-803 4lenvatinib 3fludarabine phosphate 3avelumab 3aldesleukin 3X-Rays 3Vincristine 3Surveys and Questionnaires 3Rituximab 3Phantoms, Imaging 3Paclitaxel 3Oxaliplatin 3Lenalidomide 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Withdrawn × atezolizumab × 1 year × Clear all
NCT06572722 2026-04-27

Perioperative Immunotherapy for NSCLC (ECTOP-1030)

Fudan University

Phase 2 Withdrawn
Thoracic

Lung Neoplasms

NCT06713798 2026-03-23

INDIGO

Gustave Roussy, Cancer Campus, Grand Paris

Phase 2 Withdrawn
Thoracic

Lung Neoplasms

NCT06603818 2026-02-19

Immunotherapies in Combination With Stereotactic Body Radiation Radiotherapy in Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC)

National Institutes of Health Clinical Center (CC)

Phase 2 Withdrawn
Gastrointestinal

Colorectal Neoplasms

NCT05564416 2025-10-21

Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial

National Cancer Institute (NCI)

Phase 2 Withdrawn
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT06762808 2025-08-15

Phase II Study of Atezolizumab and Tiragolumab With ctDNA for HPV-positive SCC

M.D. Anderson Cancer Center

Phase 2 Withdrawn
Tumor-Agnostic

Carcinoma, Squamous Cell

NCT06416436 2025-06-29

Dose-escalation Study of Ultra-high Dose Ablative Radiosurgery With Immunotherapy for Bulky Metastatic Cancer Patients

University of Kansas Medical Center

Phase 1 Withdrawn
Tumor-Agnostic

Neoplasm Metastasis

NCT06719973 2025-06-17

Phase 1 Study of M9466 Combined With Carboplatin and Platinum-based Anticancer Therapy (DDRiver 521)

EMD Serono

Phase 1 Withdrawn
Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡